Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Humira Biosimilar: Boehringer Faces Same Launch Hurdles As Amgen

Watch gears up close

Related Content

Biosimilar Barricade Breached: Amgen Manufacturing Patents Ruled Not Infringed

Sep 07 2016

Humira Biosimilar Interchangeability: The Race Begins

Jul 30 2017

US Approvals Roundup: Cyltezo Biosimilar, Victoza CV Benefit, Gocovri In PD, Kedrab Rabies Biologic, Gout Combo Duzallo

Aug 28 2017

AbbVie v. Amgen Round One: Humira Biosimilar Infringes 10 Patents, Suit Claims

Aug 05 2016

Boehringer Ingelheim Limbering Up With Humira Biosimilar

Jun 14 2017

Related Companies

Boehringer Ingelheim GmbH

AbbVie Inc.

Amgen, Inc.

Novartis AG

Hospira, Inc.

Pfizer Inc.

Additional Topics

United States Biosimilars Legal Issues Policy Immune Disorders BioPharmaceutical

More from Biosimilars

More from Products

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window